Drug Data Deals a Blow to Catabasis Pharmaceuticals Inc (CATB)

Catabasis Pharmaceuticals Inc (CATB) short sellers are celebrating the stock's 26% plunge

Jun 8, 2016 at 2:07 PM
facebook X logo linkedin

Biotech Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is getting crushed this afternoon, after the drugmaker's cholesterol drug failed in a mid-stage trial. At last check, the stock was down roughly 26% at $5.08, and earlier fell as far south as $4.78, putting CATB on track for its worst daily performance ever. This is business as usual for the shares, which have surrendered 36% of their value year-to-date.

CATB short sellers must be loving life right now. During the past two reporting periods, short interest on the stock spiked close to 15%. Now, 7.8% of CATB's float is sold short, which would take approximately four weeks to buy back, at the stock's typical trading levels. Of course, the shares are short-sale restricted today amid their steep sell-off.

On the other hand, it seems as though the brokerage crowd is beginning to sing a different tune. Heading into today, all three analysts tracking CATB had doled out "strong buy" recommendations. Plus, the stock's consensus 12-month price target stood at $21.50 -- record-high territory, and quadruple the shares' current perch.

Since the drug data was released, signs of pessimism have begun cropping up. Specifically, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has seen its price target cut at Wedbush (to $17), Citigroup (to $8), and Oppenheimer (to $23).

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!




Rainmaker Ads CGI